Pfizer and AstraZeneca Covid vaccines are ‘just as effective’ in the immunosuppressed, PHE says
Pfizer and AstraZeneca’s jabs are ‘just as effective’ in the immunosuppressed and patients with underlying health conditions, real-world data shows
- There were lingering fears the jabs would work less well in those at risk groups
- But first real-world data shows two doses reduce symptomatic illness risk by 74%
- This is just as effective as in rest of the population, Public Health England said
<!–
<!–
<!–<!–
<!–
(function (src, d, tag){
var s = d.createElement(tag), prev = d.getElementsByTagName(tag)[0];
s.src = src;
prev.parentNode.insertBefore(s, prev);
}(“https://www.dailymail.co.uk/static/gunther/1.17.0/async_bundle–.js”, document, “script”));
<!–
DM.loadCSS(“https://www.dailymail.co.uk/static/gunther/gunther-2159/video_bundle–.css”);
<!–
Pfizer and AstraZeneca’s vaccines are just as effective in people with underlying health conditions and the immunosuppressed, real-world data shows.
There were lingering fears the jabs would work less well in those groups because they have a harder time mounting a strong immune response.
But the first data from Britain’s vaccine rollout shows both vaccines reduce the risk of symptomatic illness by about 74 per cent after two doses.
Public Health England said the jabs were ‘as effective… in the majority of people with underlying health conditions compared to the rest of the population’.
Even after one dose, vaccine effectiveness against symptomatic disease was around 60 per cent and did not fall substantially with age.
An estimate for the jabs’ impact on severe disease, hospitalisation and death has not yet been established but it is expected to be even higher.
However, the analysis looked specifically at older versions of the virus and so the efficacy numbers could be slightly lower against the now-dominant Indian variant.
Pfizer and AstraZeneca’s vaccines are just as effective in people with underlying health conditions and the immunosuppressed, real-world data shows
Broken down, PHE said that after two doses for those aged 16 to 64, AstraZeneca/Oxford offered 78 per cent protection. No data was available for Pfizer/BioNTech.
For those aged 65 and over, two doses of Pfizer gave 89 per cent protection while AstraZeneca offered 80 per cent.
For people who are immunosuppressed, vaccine effectiveness after a second dose was 74 per cent, with similar protection to those who are not in an at-risk group.
This rises from 4 per cent after a first dose, showing the importance of a second dose.
Some health conditions are linked to an increased risk of hospital admission and death from Covid-19, including diabetes, severe asthma, chronic heart, kidney or liver disease, neurological disease, and illnesses or therapies that weaken the immune system, such as blood cancer, HIV or chemotherapy.
PHE said that protection for these people against hospital admission and death is expected to be even higher than for symptomatic Covid illness.
Dr Mary Ramsay, head of immunisation at PHE, said: ‘This real-world data shows for the first time that most people who are clinically vulnerable to Covid-19 still receive high levels of protection after two doses of vaccine.
‘It is vital that anyone with an underlying condition gets both doses, especially people with weakened immune systems as they gain so much more benefit from the second dose.’
It comes after 16 health charities joined forces to urge the Government to support around 500,000 people who are immunocompromised or immunosuppressed.
The charities included Anthony Nolan, Blood Cancer UK, Bowel Cancer UK, Cystic Fibrosis Trust and the MS Society.
Advice from the Government for the vulnerable to shield was paused on April 1 and there are currently no plans to advise people to shield again.
The charities said they wanted better communication from the Government and the NHS to inform patients, the wider public and employers about the continued risks that Covid-19 poses to immunocompromised people.
They also want employment protection and access to workplace adjustments for immunocompromised people, including the duty to consider working from home wherever possible and flexibility in start and finish times so as to avoid peak-time travel.
